Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: INO - Inovio Pharmaceuticals - A NYSE Small-Cap

16 Mar 2015 12:41 PM <--

11 Sep 2012 11:02 PM

Return to INO - Inovio Pharmaceuticals - A NYSE Small-Cap

Inovio is developing synthetic vaccines to prevent and treat cancers and infectious diseases. Our SynCon vaccines are designed to universally protect against unmatched, rapidly mutating viruses or break tolerance against cancers, and cannot cause the disease. Human studies have demonstrated best-in-class immune responses, surpassing conventional vaccine and other experimental immune stimulating technologies.